Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ANCNNASDAQ:PHIOOTCMKTS:PXYNNASDAQ:XBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANCNAnchiano Therapeutics$0.64-3.0%$21.77$0.51▼$10.55$4.75M0.933.15 million shs23,560 shsPHIOPhio Pharmaceuticals$0.68-2.8%$0.80$0.50▼$6.85$3.13M1.44366,014 shs106,030 shsPXYNPraxsyn$0.00$0.00▼$0.01N/AN/AN/AN/AXBIOXenetic Biosciences$4.09+8.2%$4.09$2.55▼$5.97$6.30M2.65,801 shs667 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANCNAnchiano Therapeutics0.00%+13.56%-7.84%+33.44%-56.21%PHIOPhio Pharmaceuticals+5.22%+11.18%-3.29%+28.34%-78.67%PXYNPraxsyn0.00%0.00%0.00%0.00%0.00%XBIOXenetic Biosciences-1.92%-5.60%-2.43%+14.77%-12.29%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANCNAnchiano TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.1414 of 5 stars3.53.00.00.00.82.50.6PXYNPraxsynN/AN/AN/AN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANCNAnchiano TherapeuticsN/AN/AN/AN/APHIOPhio Pharmaceuticals3.00Buy$4.00486.51% UpsidePXYNPraxsynN/AN/AN/AN/AXBIOXenetic Biosciences2.00HoldN/AN/ACurrent Analyst RatingsLatest PHIO, XBIO, ANCN, and PXYN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/6/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANCNAnchiano TherapeuticsN/AN/AN/AN/A$2.01 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$2.06 per shareN/APXYNPraxsynN/AN/AN/AN/AN/AN/AXBIOXenetic Biosciences$2.54M2.48N/AN/A$6.36 per share0.64Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANCNAnchiano Therapeutics-$27.12M-$3.464.27N/AN/AN/A36.08%27.40%N/APHIOPhio Pharmaceuticals-$10.83M-$5.93N/A∞N/AN/A-134.66%-105.86%5/9/2024 (Estimated)PXYNPraxsynN/AN/A0.00N/AN/AN/AN/AN/AN/AXBIOXenetic Biosciences-$4.14M-$2.75N/AN/AN/A-162.84%-36.43%-33.74%5/9/2024 (Estimated)Latest PHIO, XBIO, ANCN, and PXYN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PHIOPhio PharmaceuticalsN/A-$0.17-$0.17-$0.17N/AN/A3/21/2024Q4 2023XBIOXenetic Biosciences-$0.87-$0.77+$0.10-$0.77$0.68 million$0.67 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANCNAnchiano TherapeuticsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/APXYNPraxsynN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANCNAnchiano TherapeuticsN/A3.253.25PHIOPhio PharmaceuticalsN/A5.705.71PXYNPraxsynN/AN/AN/AXBIOXenetic BiosciencesN/A11.8411.84OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANCNAnchiano Therapeutics9.05%PHIOPhio Pharmaceuticals57.31%PXYNPraxsynN/AXBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipANCNAnchiano Therapeutics6.88%PHIOPhio Pharmaceuticals0.77%PXYNPraxsynN/AXBIOXenetic Biosciences9.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANCNAnchiano Therapeutics167.42 millionN/ANot OptionablePHIOPhio Pharmaceuticals94.59 million4.56 millionNot OptionablePXYNPraxsyn66N/AN/ANot OptionableXBIOXenetic Biosciences41.54 million1.40 millionNot OptionablePHIO, XBIO, ANCN, and PXYN HeadlinesSourceHeadlineXenetic Biosciences Inc (XBIO)investing.com - April 10 at 3:28 PMXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - March 24 at 5:09 PMXenetic Dips on Full-Year Resultsbaystreet.ca - March 22 at 7:33 PMXenetic Biosciences reports FY resultsmsn.com - March 22 at 8:51 AMXenetic Biosciences, Inc. Reports Full Year 2023 Financial Resultsaccesswire.com - March 22 at 8:00 AMXenetic to advance DNase programme with UVA partnershipmsn.com - January 18 at 1:37 PMXenetic Biosciences Inc XBIOmorningstar.com - January 4 at 5:10 PMXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecastbenzinga.com - December 11 at 9:01 AMMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensationfinance.yahoo.com - November 30 at 10:39 AMXenetic Biosciences: Q3 Earnings Insightsbenzinga.com - November 10 at 3:38 PMMediciNova: Q3 Earnings Snapshotwashingtonpost.com - November 10 at 10:37 AMXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conferencefinance.yahoo.com - October 11 at 9:30 AMXenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?msn.com - July 13 at 1:44 PMXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 11 at 5:06 PMXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | Morningstarmorningstar.com - May 5 at 10:21 AMXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Developmentfinance.yahoo.com - May 4 at 10:02 AMXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullisonfinance.yahoo.com - May 3 at 10:26 AMHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendationmsn.com - April 12 at 10:37 PMXenetic Biosciences forms research collaboration with TSRIpharmaceutical-technology.com - April 12 at 12:36 PMAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)markets.businessinsider.com - April 12 at 2:30 AMXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platformfinance.yahoo.com - April 11 at 8:43 AMJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciencesfinanznachrichten.de - March 16 at 12:09 PMJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciencesfinance.yahoo.com - March 16 at 12:09 PMXBIO Xenetic Biosciences, Inc.seekingalpha.com - February 23 at 11:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnchiano TherapeuticsNASDAQ:ANCNAnchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.PraxsynOTCMKTS:PXYNPraxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers' compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.Xenetic BiosciencesNASDAQ:XBIOXenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.